Nurtec (Rimegepant) and Carbamazepine: Drug Interaction
Nurtec (rimegepant) is not formally contraindicated with carbamazepine, but concurrent use should be avoided because carbamazepine will substantially reduce rimegepant's effectiveness.
The Core Issue: CYP3A4 Induction
Carbamazepine is a strong CYP3A4 inducer, and rimegepant is metabolized primarily through the CYP3A4 pathway. When these drugs are combined, carbamazepine dramatically accelerates rimegepant's metabolism, rendering it therapeutically ineffective.
The pharmacokinetic data demonstrates that strong CYP3A4 inducers reduce rimegepant exposure by approximately 81% 1. Specifically, when rimegepant was co-administered with rifampin (another strong CYP3A4 inducer used as a probe drug), rimegepant's area under the curve (AUC) dropped to only 19% of normal levels, and maximum concentration (Cmax) fell to 36% 1. This magnitude of reduction eliminates any meaningful therapeutic benefit.
What the FDA Label States
The FDA labeling for Nurtec lists only one contraindication: hypersensitivity reactions to rimegepant or its components 22. Carbamazepine is not listed as an absolute contraindication.
However, the absence of a formal contraindication does not mean these drugs can be safely combined. The FDA label explicitly warns against co-administration with strong or moderate CYP3A4 inducers due to the substantial loss of efficacy 1.
Clinical Recommendation
Avoid prescribing rimegepant to patients taking carbamazepine. If migraine treatment is needed in a patient on carbamazepine, consider:
- Alternative acute migraine treatments: NSAIDs combined with acetaminophen, or triptans if not contraindicated 3
- Alternative preventive treatments: Beta-blockers (metoprolol, propranolol), valproate, venlafaxine, or amitriptyline as first-line options 4
- Switching the antiepileptic: If clinically appropriate, consider transitioning from carbamazepine to an alternative antiseizure medication that doesn't induce CYP3A4
Common Pitfall to Avoid
Do not assume that simply increasing the rimegepant dose will overcome the interaction. The magnitude of enzyme induction is too substantial, and higher doses would not achieve therapeutic levels while potentially increasing adverse effects. The drug interaction studies clearly demonstrate that strong CYP3A4 inducers reduce rimegepant to subtherapeutic levels regardless of dosing 1.